Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

Inclusion Criteria: * Subjects must be undergoing a bilateral lung transplantation for end-stage lung disease and thus meet all criteria to be listed * Male or female subject, 18 -75 years of age * Subjects must sign a study specific informed consent prior to study entry * Subjects must meet all of the following laboratory values: 1. hemoglobin ≥ 6 g/dL, 2. platelets \> 75,000/mcL, 3. aspartate aminotransferase (AST/SGOT)/ alanine aminotransferase (ALT /SGPT) \< 2.5 X institutional upper limit of normal, 4. serum creatinine \< 1.5 mg/dL, 5. INR \< 1.5, PTT \< 40 seconds Exclusion Criteria: * Subject requires preoperative extracorporeal membrane oxygenation (ECMO) * Subject has second degree (Mobitz type I or II) or third-degree AV block or sinus node dysfunction * Subject has history of a bleeding diathesis * Subject has a history of clinically overt stroke within the past 3 years * Subject has a history of severe hypertension not adequately controlled with anti-hypertensive medications (Systolic blood pressure ≥ 200 mmHg and/or Diastolic blood pressure ≥ 110 mmHg) * Subjects who are receiving chronic anti-coagulation or anti-platelet therapy that would preclude surgery (prophylactic aspirin is acceptable) * Subjects with a history of metastatic cancer * Subjects with a history of seizure disorder * Subjects who are receiving or have received within 30 days any other investigational agents * Subjects who have received theophylline or aminophylline within 12 hours of study dosing